Principal Financial Group Inc. Trims Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Principal Financial Group Inc. decreased its stake in Evolus, Inc. (NASDAQ:EOLS) by 8.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,381 shares of the company’s stock after selling 2,793 shares during the quarter. Principal Financial Group Inc.’s holdings in Evolus were worth $492,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in shares of Evolus by 173.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after acquiring an additional 265,635 shares during the period. Barclays PLC raised its holdings in Evolus by 268.0% in the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock worth $1,518,000 after purchasing an additional 68,213 shares during the period. Bank of New York Mellon Corp boosted its position in Evolus by 24.6% during the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock worth $1,965,000 after purchasing an additional 35,760 shares in the last quarter. Armistice Capital LLC acquired a new stake in Evolus in the second quarter valued at approximately $3,906,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Evolus in the third quarter valued at approximately $940,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EOLS has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Friday, September 13th. Barclays boosted their price objective on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Stock Up 3.8 %

Shares of NASDAQ EOLS opened at $11.53 on Monday. The company has a market capitalization of $730.09 million, a P/E ratio of -12.67 and a beta of 1.32. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a 50 day simple moving average of $12.86 and a 200-day simple moving average of $13.76. Evolus, Inc. has a 1 year low of $9.95 and a 1 year high of $17.82.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.